• This document is an investor presentation and regulatory filing covering the financial and operational performance for the fourth quarter (Q4FY26) and full financial year (FY26) ended March 31, 2026.
  • The company has scheduled an earnings call for May 29, 2026, at 4:30 PM IST to discuss these results.
  • The stated purpose of the earnings call is to discuss the operational and financial performance of the company.
  • Management participants for the call will include: Mr. Rajeev Nannapaneni (Vice Chairman and Chief Executive Officer), Mr. Amit Parekh (Chief Financial Officer), and Mr. Rajesh Chebiyam (Executive Vice President, Crop Health Sciences).
  • The document includes a comprehensive investor presentation with detailed financial results and business updates.
  • The presentation contains standard disclaimer language indicating it includes forward-looking statements and is not an offer to sell securities.

Financial Highlights

Q4FY26 Performance:

  • Total Revenue: INR 8,169 Million
  • Pharma Export Formulations: INR 5,396 Million
  • Domestic Formulations Revenue: INR 1,087 Million
  • EBITDA: INR 2,054 Million with EBITDA Margin of 25.1%
  • Profit After Tax: INR 2,690 Million with PAT Margin of 32.9%
  • Earnings Per Share (EPS): INR 14.96 per share
  • Includes one-time tax benefit of INR 1,150 million as the company elected to move to the new tax regime and remeasured its deferred tax asset on MAT credit

FY26 Full Year Performance:

  • Earnings Per Share (EPS): INR 79.20 per share

Business Updates and Product Launches

Q4FY26 Launches:

  • Launched Semaglutide Multi Dose Vials in India at "the most affordable price"
  • Launched Pomalidomide Capsules (generic of Pomalyst) in the U.S. market

FY26 Launches and Developments:

  • Launched Everolimus tablets 1 mg (generic of Zortress) in the U.S. market
  • Launched Risdiplam for treatment of Spinal Muscular Atrophy in the Indian market
  • Launched Bosentan tablets for oral suspension, 32mg (generic of Tracleer) in the U.S. market
  • Completed strategic acquisition of 35.75% stake in Adcock Ingram Holdings Limited, South Africa

Segmental Performance (INR Million)

| Segment | Q4FY26 | Q4FY25 | Q3FY26 | FY26 | FY25 |

| API Revenue | 639 | 464 | 643 | 2,347 | 2,018 |

| Formulation - Exports | 5,396 | 10,525 | 4,214 | 32,345 | 37,597 |

| Formulation - Domestic | 1,087 | 994 | 1,198 | 4,409 | 4,000 |

| Crop Health Sciences | 226 | 150 | 285 | 1,382 | 598 |

| Other operating & non-operating income | 821 | 740 | 713 | 3,275 | 3,627 |

| Consolidated Total Revenue | 8,169 | 12,873 | 7,054 | 43,759 | 47,840 |

R&D and Investment Highlights

NCE | Cell & Gene Therapy Investments:

  • eGenesis: Invested US$8 million in xenotransplantation biotechnology
  • NRC-2694: Phase 2 clinical trial for Head and Neck cancer treatment approved by US FDA
  • Cellogen Therapeutics: Invested US$2 million in CAR-T cell therapies
  • Additional US$1 million investment in metabolic disease therapy development

Earnings Call Details

  • Date: May 29, 2026
  • Time: 4:30 PM IST
  • Dial-in Numbers provided for India, US, UK, and Singapore

Additional Notes

  • The document was filed with BSE Ltd. and National Stock Exchange of India Ltd. on May 29, 2025 (for FY25-26 presentation)
  • Signed by Venkat Ramesh Chekuri, Company Secretary & Compliance Officer
  • Includes comprehensive investor presentation deck with detailed financial statements
  • Contains forward-looking statements disclaimer and regulatory compliance language